Oricell Therapeutics, the Shanghai-based cell therapy developer, raised $100 million in its final pre-IPO financing round as it advances a GPC3-targeted autologous CAR-T for hepatocellular carcinoma. The round brings in Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners and other investors, according to an April 9 release. The company’s lead asset, Ori-C101, has completed a Phase 1 study testing three dose levels across 10 HCC patients. Oricell said the highest dose achieved an objective response and that its early dataset supports what it describes as a best-in-class efficacy and safety profile. Oricell is now planning additional studies with the goal of pursuing what it positions as the first globally approved CAR-T for HCC, while also accelerating next-generation modalities including in vivo CAR-T programs.